Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Department of Respiratory Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Lancet Respir Med. 2016 Dec;4(12):960-968. doi: 10.1016/S2213-2600(16)30317-4. Epub 2016 Oct 20.
Guidelines recommend endosonography with fine-needle aspiration for mediastinal nodal staging in non-small-cell lung cancer, but most do not specify whether this should be through endobronchial endoscopy (EBUS), oesophageal endoscopy (EUS), or both. We assessed the added value and diagnostic accuracy of the combined use of EBUS and EUS.
For this systematic review and random effects meta-analysis, we searched MEDLINE, Embase, BIOSIS Previews, and Web of Science, without language restrictions, for studies published between Jan 1, 2000, and Feb 25, 2016. We included studies that assessed the accuracy of the combined use of EBUS and EUS in detecting mediastinal nodal metastases (N2/N3 disease) in patients with lung cancer. For each included study, we extracted data on the age and sex of participants, inclusion criteria regarding tumour stage on imaging, details of the endoscopic testing protocol, duration of each endoscopic procedure, number of lymph nodes sampled, serious adverse events occurring during the endoscopic procedures, the reference standard, and 2 × 2 tables for EBUS, EUS, and the combined approach. We evaluated the added value (absolute increase in sensitivity and in detection rate) of the combined use of EBUS and EUS in detecting mediastinal nodal metastases over either test alone, and the diagnostic accuracy (sensitivity and negative predictive value) of the combined approach. This study is registered with PROSPERO, number CRD42015019249.
We identified 2567 unique manuscripts by database search, of which 13 studies (including 2395 patients) were included in the analysis. Median prevalence of N2/N3 disease was 34% (range 23-71). On average, addition of EUS to EBUS increased sensitivity by 0·12 (95% CI 0·08-0·18) and addition of EBUS to EUS increased sensitivity by 0·22 (0·16-0·29). Mean sensitivity of the combined approach was 0·86 (0·81-0·90), and the mean negative predictive value was 0·92 (0·89-0·93). The mean negative predictive value was significantly higher in studies with a prevalence of 34% or less (0·93 [95% CI 0·91-0·95]) compared with studies with a prevalence of more than 34% (0·89 [0·85-0·91]; p=0·013). We found no significant differences in mean sensitivity and negative predictive value between studies that did EBUS first or EUS first, or between studies that used an EBUS-scope or a regular echoendoscope to do EUS.
The combined use of EBUS and EUS significantly improves sensitivity in detecting mediastinal nodal metastases, reducing the need for surgical staging procedures.
No external funding.
指南推荐使用超声内镜引导下细针抽吸术对非小细胞肺癌进行纵隔淋巴结分期,但大多数指南并未具体说明是否应通过支气管内内镜(EBUS)、食管内镜(EUS)或两者联合进行。我们评估了联合使用 EBUS 和 EUS 的附加价值和诊断准确性。
我们对 MEDLINE、Embase、BIOSIS Previews 和 Web of Science 进行了系统回顾和随机效应荟萃分析,没有语言限制,检索时间为 2000 年 1 月 1 日至 2016 年 2 月 25 日期间发表的研究。我们纳入了评估联合使用 EBUS 和 EUS 检测肺癌患者纵隔淋巴结转移(N2/N3 疾病)的准确性的研究。对于每一项纳入的研究,我们提取了参与者的年龄和性别、影像学上肿瘤分期的纳入标准、内镜检测方案的详细信息、每种内镜检查程序的持续时间、采样的淋巴结数量、内镜过程中发生的严重不良事件、参考标准以及用于 EBUS、EUS 和联合方法的 2×2 表。我们评估了联合使用 EBUS 和 EUS 与单独使用任何一种方法在检测纵隔淋巴结转移方面的附加价值(敏感性和检出率的绝对增加),以及联合方法的诊断准确性(敏感性和阴性预测值)。本研究已在 PROSPERO 注册,编号 CRD42015019249。
通过数据库搜索共确定了 2567 篇独特的文献,其中 13 项研究(包括 2395 名患者)被纳入分析。N2/N3 疾病的中位患病率为 34%(范围 23%-71%)。平均而言,EUS 联合 EBUS 可提高敏感性 0.12(95%CI 0.08-0.18),而 EBUS 联合 EUS 可提高敏感性 0.22(0.16-0.29)。联合方法的平均敏感性为 0.86(0.81-0.90),平均阴性预测值为 0.92(0.89-0.93)。在患病率为 34%或更低的研究中,平均阴性预测值明显高于患病率高于 34%的研究(0.93[95%CI 0.91-0.95]比 0.89[0.85-0.91];p=0.013)。我们未发现先进行 EBUS 检查或 EUS 检查、使用 EBUS 内镜或常规超声内镜进行 EUS 检查的研究之间在平均敏感性和阴性预测值方面存在显著差异。
联合使用 EBUS 和 EUS 可显著提高检测纵隔淋巴结转移的敏感性,减少对手术分期的需求。
无外部资金。